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Abstract
Through this study, we aimed to validate several biomarkers that have been known to possibly predict the outcomes of the
trastuzumab and paclitaxel (TP). Human epidermal growth factor 2 (HER2) positive metastatic breast cancer (MBC) patients
who had been treated with TP in single institute from 2006 to 2009 were included in this study. For procured formalin fixed
paraffin embedded tumor tissues, HER2 amplification index (AI) and polymorphisms of the immunoglobulin G fragment C
receptors (FCGR) were assessed as biomarkers to the trastuzumab and expression of class III beta tubulin (bTubIII) was
evaluated as a predictive factor to the paclitaxel. Of 46 patients treated with TP, 27 patients could be evaluated for HER2 AI,
31 for bTubIII, and 26 for FCGR gene polymorphism. The median of the HER2 AI was 5.0 (range, 1.4215.5) and a higher HER2
AI ($5.0) was significantly correlated with better response rate (RR) (80% vs. 42%, P = 0.049) and longer progression-free
survival (PFS) (13.6 vs. 6.9 months, P = 0.023). High bTubIII expression showed higher RRs than did low expression (81% vs.
40%, P = 0.040) in addition to longer PFS (16.2 months vs. 8.8 months, P = 0.04). However, polymorphisms in FCGR 2A-H131R
or FCGR 3A-V158F were not predictive of RR or PFS. Our results suggest that a high HER2 AI and high bTubIII expression
could be predictive of the outcomes to TP therapy but no evidence was found in terms of FCGR polymorphisms.
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Introduction
Breast cancer is the most common cancer in women worldwide
and the second most common cause of cancer death in women [1].
Although fewer than 10% of women present with metastatic
disease at the time of diagnosis, the majority of women who
relapse after definitive therapy have disseminated disease rather
than an isolated local recurrence [2].
Human epidermal growth factor 2 (HER2) amplified in 20 to
25% of breast cancers is associated with a poor clinical outcome
[3]. Trastuzumab, a humanized monoclonal antibody directed
against the extracellular domain of HER2 is used either as a single
agent or in combination with conventional chemotherapy in
metastatic breast cancer (MBC) [4,5]. Because trastuzumab shows
synergistic cardiotoxicity when it is combined with anthracyclines,
taxane with trastuzuamab combination therapy is considered
a first-line option in metastatic breast cancer [6]. However, the
response rate of trastuzumab and paclitaxel (TP) combination
therapy is around 36241% [5,7], which means the identification
of predictive markers for clinical efficacy is an important issue in
the management of HER2 positive MBC.
The mechanism of the antitumor activity of trastuzumab is
referred to be not only direct anti-proliferative effects [8], but
effects on the immune system, including antibody-dependent cell-
mediated cytotoxicity (ADCC) and complement-mediated cyto-
toxicity [9]. In ADCC, trastuzumab binds to tumor cells and is
engaged by effecter cells via their immunoglobulin G receptor.
Musolino et al. reported that the efficacy of trastuzuamab is
associated with immunoglobulin G fragment C receptor (FCGR)
polymorphisms [10]. Also, there were reported that the magnitude
of HER2/neu amplification might be a predictive marker for the
use of trastuzuamab [11,12]. In terms of paclitaxel, beta tubulin
and p-glycoprotein expression were suggested to be associated with
response to paclitaxel [13,14]. Especially, the expression of class
III beta tubulin (bTubIII) was reported to be associated with
response to taxane in many cancer types such as non-small cell
lung, breast, ovarian, and gastric cancers [13].
With this background, we aimed to address possible predictive
biomarkers for HER2-positive metastatic breast cancer patients
treated with trastuzuamab and paclitaxel.
Results
Patient Characteristics
The clinicopathologic features of 46 patients treated with
trastuzumab and paclitaxel are listed in Table 1. All the enrolled
patients were HER2 positive according to either immunohisto-
chemistry (IHC) or the fluorescence in situ hybridization (FISH)
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criteria. The median age was 53 years (range, 33269 years). The
median HER2 AI was 5 (range, 1.4215.5). Prior (neo) adjuvant
chemotherapy was performed in 21 patients (40%) and the
remaining 25 patients were chemotherapy naı¨ve metastatic disease
from the initial presentation.
Clinical Outcomes
Forty patients (87%) have completed six cycles of paclitaxel and
trastuzumab and continued on following trastuzumab mainte-
nance therapy. Response evaluation was performed in 44 patients.
Two patients were missed because one died from pneumonia
followed by septic shock after the first cycle of chemotherapy and
the other was lost to follow-up after the first cycle of therapy. In the
remaining 44 patients, the overall response rate was 63.6%,
including complete response (CR) in five (11.3%) and partial
response in 23 (52.3%) (Table 2). Two patients with cervical neck
node metastasis achieved CR after six cycles of the trastuzumab
and paclitaxel (TP), and then one patient received radiotherapy on
neck node and the other underwent neck node dissection and
finally reported pathologic CR. Two patients who had liver and
lung metastasis showed radiologic CR after six courses of TP and
one patients developed controlateral breast metastasis after 24
months of trastuzuamab treatment and one patient was lost to
follow-up after 9 months of treatment. The last patient who had
metastasis in the brain alone underwent radiosurgery and CR has
been observed for 14 months. The median progression-free
survival (PFS) was 12.6 months [95% confidence interval (CI),
7.7219.5 months] and the median OS was not reached with
median follow-up of 23.6 months (Figure 1).
Predictive Factors
Table 3 shows response rates (RRs) according to clinicopath-
ologic parameters and markers evaluated as potential predictive
factors. Tissue was available for bTubIII expression analysis in 31
patients (67.4%) and the median IHC expression score for
bTubIII was 40% (range, 0290%). At an IHC cutoff score of
40%, bTubIII expression was high in 21 (67.7%) and low in 10
patients (Figure 2). Patients with bTubIII-high tumors showed an
81% response rate compared to 40% in patients with bTubIII-low
tumors (P = 0.045). Patients with bTubIII-high tumors also
showed a longer PFS than bTubIII-low tumors (16.2 months vs.
8.8 months, P= 0.04) (Figure 3).
In the 27 patients for whom HER2 FISH data were available,
HER2 AI varied from 1.4 to 15.4, and the median AI was 5.
Patients with a low HER2 AI (,5) had a lower response rate (RR)
(41.7% vs. 80%, P= 0.049) and a significantly shorter survival
Table 1. Characteristics of the patients.
Characteristics Patients
No %
No. of patients 46 100
Median age, years 53
Range 33269
Menopause status
Pre- 15 32.6
Post 31 67.4
Performance status
0 20 43.5
1 22 47.8
2 4 8.7
Estrogen receptor status
Positive 24 52.1
Negative 22 47.9
Progesterone receptor status
Positive 26 56.5
Negative 20 43.5
HER2 status (IHC)
2+ 5 10.9
3+ 41 89.1
HER2 status (FISH)
Amplification index, median 5
Range 1.4215.5
Disease status at diagnosis
Relapsed 26 56.5
Initial metastatic 20 43.5
Metastasis site
Chest wall + regional lymph nodes 34 73.9
Lung 27 58.7
Liver 13 28.3
Bone 28 60.9
Brain 5 10.9
Prior therapy for breast cancer
Neo/adjuvant chemotherapy 17 40
Anthracyclines 9 52.9
Taxane 6 35.3
Adjuvant hormone therapy 5 10.9
Adjuvant radiotherapy 10 21.7
HER2, Human epidermal growth factor 2; IHC, Immunohistochemistry; FISH,
Fluorescent in situ hybridization.
doi:10.1371/journal.pone.0045127.t001
Figure 1. Kaplan-Meier estimates of median progression-free
survival (PFS, dotted line) and overall survival (OS, straight
line) for all patients (N=46). The median survival of PFS is 12.6
months and the median OS was not yet reached.
doi:10.1371/journal.pone.0045127.g001
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than high HER2 AI group (6.9 months vs. 13.6 months, P= 0.023)
(Figure 4).
FCGR polymorphisms were evaluated in 26 patients. The
frequencies of FCGR 2A-H131R genotypes were H/H 50%, H/R
46.2%, and R/R 3.8%. For FCGR 3A-V158F, frequencies were
V/V 3.8%, V/F 34.6%, and F/F 61.6%. However, no differences
in either RR or PFS according to FCGR polymorphism were
observed.
Good performance status [Eastern Cooperative Oncology
Group (ECOG) 0 or 1], high expression of bTubIII, and high
HER2 AI were significantly associated with PFS. However, they
were not observed to be independent predictive markers for PFS
by multivariate analysis (Table 4).
Toxicity
In general, treatments were well tolerated and the majority of
adverse events were of mild to moderate severity (Table 5). One
patient experienced treatment-related death from pneumonia with
septic shock after receiving the first cycle of chemotherapy, and G3
or 4 neutropenia was seen in 11 patients (23.9%). The most
common nonhematologic toxicity was peripheral neuropathy and
paclitaxel was discontinued in one patient for grade 3 neuropathy
after four treatment cycles. There were no cases of grade 3 or 4
cardiac dysfunction, while 8 of the 46 patients (16.5%) developed
asymptomatic grade 1 or 2 left ventricle dysfunction.
Discussion
The aim of this study was to validate predictive markers for the
efficacy of paclitaxel and trastuzuamab in recurrent or metastatic
breast cancer patients. We found that overexpression of bTubIII
and amplified HER2 genes predicted good response and favorable
progression free survival in HER2-positive breast cancer patients
treated with paclitaxel and trastuzuamab.
Preclinical studies have reported that overexpression of bTubIII
is associated with taxane resistance in many cancer cell lines [15–
18]. In a clinical setting, high levels of bTubIII expression predict
lower response and poor outcomes in non-small cell lung cancer,
ovarian cancer, breast cancer, and primary unknown-site cancer
[19–22]. However, we found the contrary results, with patients
with high bTubIII expression having a higher RR and longer PFS
than those with low bTubIII expression. This results are consistent
with some other studies reporting that overexpression of bTubIII
is associated with good response and favorable prognosis in
ovarian cancer, non-small cell cancer and breast cancer [23–25].
The reason for this discrepancy is not yet known. However,
potential explanations include that currently validated predictive
markers are mixed predictive and prognostic factors [26].
According to Reinman et al., high bTubIII expression is a poor
prognostic factor for non-small cell lung cancer patients treated
with surgery alone, although the benefit of adjuvant chemotherapy
Table 2. Response to therapy.
Response Evaluable patients (n =44)
No. (%)
Complete response 5 11.3
Partial response 23 52.3
Stable disease 15 34.1
Progressive disease 1 2.3
Overall response rate 28 63.6
doi:10.1371/journal.pone.0045127.t002
Figure 2. A and B were representative staining for class III beta tubulin in invasive carcinoma of the mammary gland; absence of
staining (A), and strong staining(B).
doi:10.1371/journal.pone.0045127.g002
Figure 3. Kaplan-Meier curves comparing PFS according to
expression of class III beta tubulin. The patients with high
expression of bTubIII tumors had significant longer PFS compared with
those with low-expression tumors (16.2 months vs. 8.2 months,
p = 0.004).
doi:10.1371/journal.pone.0045127.g003
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was greater in patients with high bTubIII expression [24]. This is
similar to the story of HER2 in breast cancer, where HER2 is
a poor prognostic marker but a good predictive marker to
trastuzumab [27]. A second explanation is that studies were
different each other in terms of cut-off levels for bTubIII positivity
and chemotherapy agents combined with taxane. The third
explanation is differential predictive implications in early [24]
versus advanced settings [19] or in serous cell-type ovarian
carcinoma [20] versus clear cell ovarian carcinoma [23]. Another
possible cause of discrepancies is the limitations of each study, such
as retrospective design, small sample size, or heterogeneity of the
eligible patients (with different numbers of previous lines of
treatment).
The influence of FCGR genotype on treatment outcome has
been reported in breast cancer [10] and other malignancies [28–
30]. According to the report from Dr. Musolino, a significant
difference in RR was observed between patients with FCGR 3A
V/V and those with either 158 V/F or 158 F/F genotype (82%
v 42% v 35%; P= .03) [10]. However, we found no difference in
RR or survival according to FCGR polymorphism in our study.
Fifty-six patients would be needed to detect a difference in RR
based on genotypes of FCGR (in the Musolino’s study) at a power
of 80% and p-value of 0.05 using Fisher’s exact test. Accordingly,
our study did not meet the statistical power, because genotypes of
FCGF were performed in only 26 patients. However, the
genotypes frequencies and clinical responses according to
genotypes of FGFR were quite different between this study and
Musolino’s study (Supplementary table S1). In our study, VV
type of FCGR 2A was identified in only one patient (3.5%),
which was a much lower incidence than Musolino’s data
(20.4%), and the RR according to FV and FF genotypes were
quite similar with 66.7% and 68.7%, respectively (p = 0.927)
(Supplementary table S1). Therefore, even if the sample size in
our study was increased, a difference of RR based on FCGR 3A
genotypes might not be observed. Like the this study, the recently
reported largest analysis to evaluate the association between
FCGR polymorphisms and trastuzuamab efficacy in HER-2-
positive breast cancer failed to confirm results from previously
published smaller studies [31].
Regardless of strong points that this study was performed in
quite homogenous group of patients, that is, HER2 positive
MBC breast cancer patients who received TP as the first line
therapy and that all the test was performed prospectively with
the help of the independent pathologist, it has several
limitations. First, we had a small sample size and the three
markers (bTubIII, HER2 FISH ratio, and FCGR polymor-
phism) were evaluated in only part of the patients because of
limited available tumors and blood samples. Second, our follow-
up duration was insufficient. At a median follow-up of 23.6
months, 31 of 46 patients (67.4%) experienced disease pro-
gression and only 11 deaths (23.9%) had occurred. Therefore,
the association between several factors and OS could not be
evaluated. Consequently, these factors should be validated in
large populations with long-term follow-up.
In conclusion, we found that high bTubIII expression and
high HER2 AI are good predictive markers for RR and
favorable prognosis in HER2-positive metastatic breast cancer
patients treated with paclitaxel and trastuzuamab. However, no
evidence was found supporting an effect of FCGR polymorph-
Table 3. Clinical response according to baseline
characteristics and biomarkers.
Number (%) Response (%) P-value
CR/PR SD/PD
Age 0.104
,60 28 (63.6) 15 (53.6) 13 (46.4)
$60 16 (36.4) 13 (81.3) 3 (18.8)
Performance status 0.652
021 38 (86.4) 25 (65.8) 13 (34.2)
2 6 (13.6) 3 (50) 3 (50)
Hormone receptor status 0.521
Negative 16 (36.4) 12 (75) 4 (25)
Positive 28 (63.6) 18 (64.3) 10 (35.7)
No. of metastasic site 0.336
021 16 (36.4) 4 (25) 12 (75)
$3 28 (63.6) 17 (60.7) 11 (39.3)
FCGR 2A (n = 26)
HH 13 (50) 8 (61.5) 5 (38.5) 0.89
HR 12 (46.2) 9 (75) 3 (25)
RR 1 (3.8) 1 (100) 0
FCGR 3A (n = 26) 0.927
VV 1 (3.5) 1 (100) 0
FV 9 (34.6) 6 (66.7) 3 (66.3)
FF 16 (61.5) 11 (68.7) 5 (31.3)
FISH ratio (n = 27) 0.049
,5 12 (44.4) 5 (41.7) 7 (58.3)
$5 15 (55.6) 12 (80) 3 (20)
Expression of bTubIII
(n = 31)
0.04
Low 10 (32.3) 4 (40) 6 (60)
High 21 (67.7) 17 (81) 4 (19)
FCGR, Immunoglobulin G fragment C receptors; FISH, Fluorescent in situ
hybridization. CR, complete response; PR, partial response; SD, stable diseases;
PD, progression of disease.
doi:10.1371/journal.pone.0045127.t003
Figure 4. Kaplan-Meier estimates of PFS according to HER2
FISH amplification index (AI). The patients with high HER2 FISH AI
tumors had significant.
doi:10.1371/journal.pone.0045127.g004
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isms on therapeutic benefit of the trastuzuamab. Large scaled
prospective studies are needed to confirm the roles of these
biomarkers in HER2-positive breast cancer patients treated with
TP.
Methods
Patients
We recruited 46 women with HER2 positive metastatic or
recurrent breast cancer. All of the patients underwent biopsy of
a primary or recurred breast tumor before the first-line
chemotherapy with trastuzumab and paclitaxel at the Yonsei
Table 4. Univariate and multivariate analysis for progression free survival.
Univariate analysis Multivariate analysis
Median months (95% CI) P-value Hazard ratio (95% CI) P-value
Age 0.064
,60 12.2 (8.7215.7)
$60 15.7 (7.4223.9)
Performance status 0.01 0.18
021 13.6 (8.6218.6) 1
2 5.8 (4.627.1) 2.45 (0.6629.51)
Hormone receptor status 0.392
Negative 15.7 (11.4219.9)
Positive 10.8 (8.3213.2)
No. of metastasic site 0.14
021 13.9 (9.2218.5)
$3 10.8 (4.6217.0)
FCGR 2A 0.836
HH 16.2 (13.8218.6)
HR/RR 25.0 (2.2247.9)
FCGR 3A 0.537
VV/FV 11.8 (9.1214.5)
FF 25.0 (10.8239.2)
Expression of bTubIII 0.04 0.164
Low 8.8 (4.6213.0) 1
High 16.2 (11.4221.0) 0.47 (0.1721.36)
FISH ratio 0.023 0.184
,5 6.9 (6.127.7) 1
$5 13.6 (11.1216.0) 0.46 (0.1521.44)
CI, Confidence interval; FCGR, Immunoglobulin G fragment C receptors; FISH, Fluorescent in situ hybridization.
doi:10.1371/journal.pone.0045127.t004
Table 5. Hematological and non-hematological toxicities.
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
No. % No. % No. % No. %
Hematological
Neutropenia 7 15.2 9 19.6 6 13 5 10.9
Anemia 10 21.7 5 10.9 3 6.5 0 0
Thrombocytopenia 2 4.3 2 4.3 1 2.2 0 0
Non-hematological
Nausea and vomiting 5 10.9 2 4.3 0 0 0 0
Neuropathy 10 10.9 11 23.4 1 2.1 0 0
LV dysfunction 5 10.9 3 6.5 0 0 0 0
LV, Left ventricle.
doi:10.1371/journal.pone.0045127.t005
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University Health System between September 2006 and October
2009.
Paclitaxel (175 mg/m2 i.v., every three weeks) and trastuzumab
(4 mg/kg i.v., as a loading dose, then 2 mg/kg weekly) were
administered to patients with HER-2-positive metastatic breast
cancer as the first-line chemotherapy. Six cycles of combination
therapy with paclitaxel and trastuzumab were administered
followed by trastuzumab until disease progression. The study
was approved by the institutional review board. Tumor assess-
ments were performed every two cycles, and disease response was
categorized as complete response (CR), partial response (PR),
stable disease (SD), and progressive disease (PD) according to the
response criteria in solid tumor (RECIST, version 1.1) criteria
[32]. Toxicity was scored every 3 weeks according to the Common
Toxicity Criteria of the National Cancer Institute (NCI-CTC,
version 4.1) [33].
HER2 Positivity and Amplification Index
Serial 4-mm sections of tissue were used for both IHC and FISH
test for HER2. IHC was performed using a Hercep Test Kit
(DAKO, Carpinteria, CA) and results were interpreted semi-
quantitatively using scale values of 0, 1+, 2+, and 3+ according to
the manufacturer’s recommended scoring system. Scoring was
conducted by a pathologist unaware of the patients’ clinical
information. FISH was performed using a PathVysin HER2 DNA
probe kit (PathVysin; Vysis, Stuttgart-Faranenhof, Germany) and
was analyzed as previously described [34]. The HER2 amplifica-
tion index (AI) was defined as the number of HER2/neu signals
per nucleus relative to the number of chromosome 17 centromere
signals per nucleus in FISH. Tumor were considered to be
amplified if this ratio was greater than two and amplified tumors
were further categorized as lower amplified or higher amplified
group with the cut-off value of the median HER2 AI in whole
recruited patients. HER2 positivity was defined as an intensity of
3+ according to IHC or as gene amplification in FISH.
IHC for bTubIII
Expression of bTubIII was evaluated using IHC with a primary
antibody against bTubIII (1:50, Etipomics, 1967-1, USA). To
evaluate bTubIII expression, 4-mm tissue sections were depar-
affinized in xylene, rehydrated and treated with 2.5% H2O2 for
10 min to block endogenous peroxidase. Slides were subjected to
heat-induced antigen retrieval for 2 min in 10 mmol/L citrate
buffer (pH 7). After washing with peripheral blood smear
examination (PBS), slides were incubated with primary antibody
for 90 min at room temperature. A second PBS wash was followed
by incubation at room temperature for 30 min with a mouse
secondary antibody and another PBS wash. Color development
occurred via incubation with 0.5% 3,3-diaminobenzidine solution
for 1 min. After washing with PBS, the slides were stained with
Harris hematoxylin and submitted for interpretation. Immunore-
activity for bTubIII was evaluated in three areas per slide for
correlation and confirmation of the tissue diagnosis. The number
of tumor cells with cytoplasmic staining of bTubIII was counted.
Possible scores ranged from 0 to 100%. Cutoffs for definition of
‘‘low’’ or ‘‘high’’ expression of bTubIII by IHC were defined
based on the median values observed in the patient population.
FCGR Polymorphisms
Peripheral blood (10 cc) was obtained from enrolled patients
who provided signed informed consent for blood analysis.
Genomic DNA was purified from leukocytes after selective lysis
of erythrocytes using an automated DNA extractor, according to
the manufacturer’s instructions (Applied Biosystems, Foster City,
CA). FCGR 2A genotyping was performed on genomic DNA
using polymerase chain reaction (PCR) and polymorphism
assignment determined by restriction enzyme digestion, followed
by agarose gel electrophoresis, using previously described methods
[35]. FCGR3A genotyping was performed using allele-specific
PCR methods as previously described [36].
Statistical Methods
Clinical characteristics and response rates were compared based
on bTubIII expression, HER2 AI, and FCGR polymorphisms
using a x2 test or Fisher’s exact test. Survival estimates were
calculated using the Kaplan-Meier method. PFS was calculated
from the first date of chemotherapy to the date of disease
progression or of death from any cause. Differences in PFS
according to expression of bTubIII, HER2 AI, and FCGR
polymorphism were compared using the log-rank test. Multivar-
iate analysis used Cox’s proportional hazard model to define
independent prognostic factors for hazard ratios, and the 95% CI
was estimated for significant values according to univariate
analysis. Statistical data were obtained using SPSS software,
version 12.0 (SPSS Inc, Chicago, IL).
Ethics Statement
The study was done in accordance with the Declaration of
Helsinki. This study was approved by the Institutional Review
Board of Yonsei University Health System (4-2009-0166). We
received written informed consent from the patients who were
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